SAN FRANCISCO--(BUSINESS WIRE)--Amplitude, Inc. (Nasdaq: AMPL), a leading digital analytics platform, today announced the results of the Total Economic Impact™ of Amplitude study conducted by ...
(RTTNews) - Johnson & Johnson (JNJ) Tuesday reported encouraging results from the Phase 3 AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate (Akeega) plus prednisone in ...
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results